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Abstract
Background: The objective of this study was to investigate whether the levels of glucose or certain amino acids
could regulate the expression of a cell cycle repressor protein p27(Kip1), thereby dictating the risk of cancer in
either obesity or caloric/dietary restriction. Previously, we identified and reported four different upstream molecular
signaling pathways of p27 expression in human breast cancer cells. We called these four pathways as pathway #1,
#2, #3 and #4. We found that 4-hydroxytamoxifen - but not tamoxifen - up-regulated the expression of p27 using
pathway #1 which consisted mainly of receptor tyrosine kinases and mTORC1. We now investigate, using 4-
hydroxytamoxifen as a reference anti-cancer agents, whether (a) the moderate increase in the concentration of D-
(+)-glucose could down-regulate and, conversely, (b) the deficiency of D-(+)-glucose or certain L-amino acids could
up-regulate the expression of p27 in these cells using pathway #2 which consists mainly of AMPK and mTORC1.
Results: Using human MDA-MB-231 breast cancer cells in vitro, these hypotheses were tested experimentally by
performing p27-luciferase reporter transfection assays and western immunoblot analyses. The results obtained are
consistent with these hypotheses. Furthermore, the results indicated that, although 4-hydroxytamoxifen used
primarily pathway #1 to down-regulate the phosphorylation of 4E-BP1 and up-regulate the expression of p27, it
also secondarily down-regulated the phosphorylation of S6K1. In contrast, the deficiency of D-(+)-glucose or L-
leucine used primarily pathway #2 to down-regulate the phosphorylation of S6K1, but they also secondarily down-
regulated the phosphorylation of 4E-BP1 and up-regulated the expression of p27. Finally, deficiency of D-
(+)-glucose or L-leucine - but not 4-hydroxytamoxifen - up-regulated the expression of mitochondrial ATP5A and
SIRT3.
Conclusions: (a) 4-Hydroxitamoxifen used primarily pathway #1 to up-regulate the expression of p27. (b) Moderate
increase in the concentration of D-(+)-glucose used primarily pathway #2 to down-regulate the expression of p27.
(c) Deficiency of D-(+)-glucose or L-leucine also used primarily pathway #2 to up-regulate the expression of p27.
(d) Deficiency of D-(+)-glucose or L-leucine - but not 4-hydroxytamoxifen - up-regulated the expression of
mitochondrial ATP5A in the Complex V of respiratory oxidation-phosphorylation chain and mitochondrial SIRT3.
The SIRT3 is one of the seven mammalian anti-aging as well as anti-metabolic sirtuins.
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The risk of developing cancer is increased in obesity
where the serum levels of glucose, certain amino acids,
insulin and other growth factors tend to be elevated.
Conversely, the risk of developing cancer is decreased in
caloric/dietary restriction where the serum levels of
these metabolites tend to be reduced. The objective of
this study was to investigate whether the levels of glu-
cose or certain amino acids could regulate the expres-
sion of a cell cycle repressor protein p27(Kip1), thereby
dictating the risk of cancer in either obesity or caloric/
dietary restriction.
p27 is a member of the family of cyclin-dependent
kinase (CDK) inhibitors (CDIs). p27 binds to certain
cyclin/CDK complexes, arrests the cell cycle progression
from G1 to S phase and inhibit DNA replication. It is
known that a relatively large number of nutritional and
chemopreventive anti-cancer agents - including 4-hydro-
xytamoxifen - specifically up-regulate the expression of
p27 in both estrogen receptor (ER)-positive and -nega-
tive human breast cancer cells in vitro [1,2]. It is also
known that some other anti-cancer agents specifically
up-regulate the expression of p27 in either ER-positive
or -negative human breast cancer cells in vitro [1,2].
p27 exhibits a set of unique characteristics that are
not seen in other G1-to-S phase cell cycle regulatory
proteins [1,2]. First, various anti-cancer agents specifi-
cally up-regulate the expression of p27 without directly
affecting expression of other G1-to-S phase cell cycle
regulatory proteins including INK4s, p57(Kip2), p21
(Cip1Waf1), D-type cyclins, cyclin E, cyclin A, CDK2,
CDK4 and CDK6 [1-3]. Secondly, the degree of up-regu-
lation of the expression of p27 in human breast cancer
cell lines in vitro by these anti-cancer agents linearly
and positively correlates with the degree of inhibition of
methylnitrosourea (MNU)-induced rat mammary adeno-
carcinoma in vivo by the same anti-cancer agents [2].
This linear and positive correlation could not be held if
a particular anti-cancer agent must be converted to an
active metabolite in vivo in order to up-regulate the
expression of p27. An example of such anti-cancer
agent is tamoxifen which must be converted to 4-hydro-
xytamoxifen in vivo to specifically up-regulate the
expression of p27. Lastly, unlike other G1-to-S phase
cell cycle regulatory proteins, expression of p27 is not
r e g u l a t e da tt h el e v e lo ft r a n s cription, but primarily at
the level of translation. It was observed in the 1980s and
1990s that, during the progression of cell cycle, the level
of p27 protein expression oscillated cyclically, but the
level of p27 mRNA remained constant. This observation
led investigators to suggest that, during the cell cycle,
expression of p27 is regulated primarily at the level of
translation [4-10]. It was also proposed that the expres-
sion of p27 during the progression of cell cycle could be
regulated by various other post-translational mechan-
isms including ubiquitin-proteasome-induced degrada-
tion [11-14], complex formation [15], subcellular
localization [16-21] and phosphorylation [21-23]. Based
on the results of our previous studies [1,2], we believe
that a large number of anti-cancer agents up-regulate
the expression of p27 primarily by activating the rate of
translation initiation of p27 mRNA.
Despite all these information, however, very little is
known about the upstream molecular signaling pathways
of how various anti-cancer agents specifically up-regu-
late the expression of p27 in human breast cancer cells
in vitro. Previously, we identified and reported four dif-
ferent upstream molecular signaling pathways of p27
expression by using p27-luciferase reporter plasmids,
western immunoblot analysis and numerous specific
inhibitors and stimulators of p27 expression [1,2]. (We
will call these four pathways as #1, #2, #3 and #4.).
We also reported previously that, in both ER-positive
and -negative human breast cancer cells in vitro,4 -
hydroxytamoxifen (4-OH-tamoxifen) - but not tamoxi-
fen - up-regulated the expression of p27 by using path-
way #1 which consists mainly of receptor tyrosine
kinases (RTKs) and mammalian target of rapamycin
complex 1 (mTORC1) [2].
We now hypothesize that moderate increase in the
concentration of D-(+)-glucose down-regulates the
expression of p27 in human breast cancer cells in vitro
by using pathway #2 which consists mainly of 5’-AMP-
activated protein kinase (AMPK) and mTORC1. Con-
versely, we also hypothesize that deficiency of D-(+)-glu-
cose or certain L-amino acids up-regulates the
expression of p27 in these cells by using the pathway #2
To test these hypotheses, we performed p27-luciferase
reporter transfection assays and western immunoblot ana-
lyses using ER and LKB1-double negative human MDA-
MB-231 breast cancer cell in vitro.T h er e s u l t so b t a i n e d
were consistent with these hypotheses. Additional results
were also obtained that indic a t e dt h a td e f i c i e n c yo fD -
(+)-glucose or L-leucine - but not 4-hydroxytamoxifen -
up-regulated the expression of mitochondrial ATP
Synthase a chain (ATP5A) in the Complex V of respira-
tory oxidation-phosphorylation chain and mitochondrial
SIRT3 in these cells. The SIRT3 is one of the seven mam-
malian anti-aging and anti-metabolic sirtuins.
Results
4-Hydroxytamoxifen - but not tamoxifen - up-regulated
the expression of p27 in estrogen receptor (ER) and
LKB1-double negative human MDA-MB-231 breast cancer
cells in vitro
The effects of 4-hydroxytamoxifen (4-OH-tamoxifen)
and tamoxifen on the expression of p27 in human
breast cancer cells in vitro were investigated using p27-
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proximal 5’-upstream regions of p27 gene, namely -1797
p27 (p27-Kpn I), -774 p27 (p27-Apa I), and -575 p27
(p27-5’UTR) (Figure 1a). These plasmids were trans-
fected into ER and LKB1-double negative human MDA-
MB-231 breast cancer cells in vitro and then the trans-
fected cells were exposed to DMSO or 1 μM each of
tamoxifen or 4-OH-tamoxifen for 24 hours. The results
indicated that tamoxifen did not up-regulate the relative
luciferase activity of p27 (Figure 1b), but 4-OH-tamoxi-
fen up-regulated it in these cells (Figure 1c). Previously,
we reported essentially thes a m er e s u l t su s i n gE Ra n d
LKB1-double positive human MCF7 breast cancer cells
in vitro [1,2].
Additionally, the results of these studies, along with
those of our previous studies [1,2], were consistent with
the hypothesis that the expression of p27 is regulated
primarily at the level of translation. For more informa-
tion about this issue, please go to the Methods section
below,
Based on these results, we constructed a schematic
d i a g r a m( F i g u r e1 d )s h o w i n gt h eo u t l i n eo fh o w4 - O H -
tamoxifen could up-regulate the expression of p27,
down-regulate the cell cycle progression from G1 to S
phase, thereby inhibiting the DNA replication of the
human breast cancer cells in vitro.
Moderate increase in the concentration of D-(+)-glucose
down-regulated the expression of p27, and, conversely,
deficiency of D-(+)-glucose, L-leucine, L-methionine, L-
cysteine or combination of L-methionine and L-cysteine
up-regulated the expression of p27 in human MDA-MB-
231 breast cancer cells in vitro
The effects of (a) moderate increase in the concentra-
tion of D-(+)-glucose and (b) deficiency of D-(+)-glu-
cose, L-leucine, L-methionine, L-cysteine or
combination of L-methionine and L-cysteine on the
expression of p27 in MDA-MB-231 cells were investi-
gated using one of the luciferase reporter plasmids con-
taining a proximal 5’-upstream region of p27 gene (-575
p27-5’UTR) (Figure 2a).
The results indicated that moderate increase in the
concentration of D-(+)-glucose down-regulated the rela-
tive luciferase activity of -575 p27-5’UTR in MDA-MB-
231 cells (Figures 2b). In contrast, deficiency of D-
(+)-glucose, L-leucine, L-methionine, L-cysteine or com-
bination of L-methionine and L-cysteine up-regulated
the relative luciferase activity of p27 in these cells (Fig-
ure 2c). It should be noted that deficiency of the combi-
nation of L-methionine and L-cysteine up-regulated the
relative luciferase activity of p27 more than the defi-
ciency of individual amino acids.
The results (Figure 2b) also indicated that (a) rotenone
(inhibitor of NADH dehydrogenase (Complex 1) of the
mitochondrial respiratory oxidation-phosphorylation
chain) and AICA riboside (inhibitor of AMPK (5’-AMP-
activated protein kinase)) up-regulated the relative luci-
ferase activity of p27 in MDA-MB-231 cells, but (b)
compound C (activator of AMPK) down-regulated the
relative luciferase activity of p27 in these cells. Metfor-
min did not either up or down-regulate the relative luci-
ferase activity of p27 probably because MDA-MB-231
cells lack LKB1.
Differential effects of 4-hydroxytamoxifen and deficiency
of D-(+)-glucose on the upstream molecular signaling
pathways of the expression of p27: pathways
immediately downstream of mTORC1 (mammalian target
of rapamycin complex 1)
Previously, we identified and reported four different
upstream molecular signaling pathways of p27 expres-
sion that could lead to either activation or inactivation
of the translation initiation of p27 mRNA through its
unusually long 5’-untranslated region (5’-UTR) (-575) of
p27 mRNA (Figure 3a and 3b) [2]. We also reported
previously that 4-hydroxytamoxifen (4-OH-tamoxifen)
up-regulated the expression of p27 by using pathway #1
which consists mainly of receptor tyrosine kinases
(RTKs) and mTORC1 (Figure 3a) [2]. We now hypothe-
size that (a) moderate increase in the concentration of
D-(+)-glucose down-regulates and, conversely, (b) defi-
ciency of D-(+)-glucose or certain L-amino acids up-reg-
ulates the expression of p27 by using pathway #2 which
consists mainly of AMPK (5’-AMP-activated protein
kinase) and mTORC1 (mammalian target of rapamycin
complex 1) (Figure 3a).
To begin to test these hypotheses, we first performed
the western immunoblot analysis of the expression of
p27 protein itself. The resul t s( F i g u r e s3 c ,da n d3 e )
indicated that 4-OH-tamoxifen and deficiency of D-
(+)-glucose or L-leucine up-regulated the expression of
p27 protein, but deficiency of L-methionine or L-
cysteine did not in MDA-MB-231 cells.
In order to look more closely into the effects of 4-
OH-tamoxifen and deficiency of D-(+)-glucose or cer-
tain L-amino acids on the upstream molecular signaling
pathways #1 and #2 of the expression of p27, western
immunoblot analyses were performed to investigate the
proteins immediately downstream of mTORC1, namely
eukaryotic translation initiation factor 4E binding pro-
tein 1 (4E-BP1) and p70 S6 kinase 1 (S6K1).
(a) Differential effects on the phosphorylation of 4E-BP1
Figure 4a to 4e show that (a) 4-OH-tamoxifen and (b)
deficiency of D-(+)-glucose or L-leucine did not either
down or up-regulate the expression of total 4E-BP1, but
they down-regulated the phosphorylated 4E-BP1. As
summarized in Figure 4f, the degree of down-regulation
of the phosphorylated 4E-BP1 appeared to be positively
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Page 3 of 17Figure 1 4-Hydroxytamoxifen - but not tamoxifen - up-regulated the expression of p27 in estrogen receptor (ER) and LKB1-double
negative human MDA-MB-231 breast cancer cells in vitro. (a) Schematic drawing of the luciferase reporter plasmids containing the
following proximal 5’-upstream regions of the p27 gene, namely -1797 p27 (p27-Kpn I), -774 p27 (p27-Apa I), and -575 p27 (p27-5’UTR). (b)
Tamoxifen did not up-regulate the relative luciferase activity of p27-Kpn 1, Apa I or 5’UTR in MDA-MB-231 cells (c) 4-Hydroxytamoxifen up-
regulated the relative luciferase activity of the three p27- luciferase reporter plasmids in MDA-MB-231 cells. In all experiments, the cells were
exposed to either DMSO or 1 μM each of tamoxifen or 4-hydroxytamoxifen for 24 hours. All assays were performed in triplicates and repeated
three times. (d) Schematic diagram showing how 4-hydroxytamoxifen could up-regulate the expression of p27, arrest the progression of cell
cycle from G1 to S phase, and inhibit DNA replication.
Eto Cancer Cell International 2011, 11:31
http://www.cancerci.com/content/11/1/31
Page 4 of 17Figure 2 Moderate increase in the concentration of D-(+)-glucose down-regulated, but deficiency of D-(+)-glucose, L-leucine, L-
methionine, L-cysteine or combination of L-methionine and L-cysteine up-regulated the relative luciferase activity of p27-5’UTR in
human MDA-MB-231 breast cancer cells in vitro. (a) Schematic drawing of the luciferase reporter plasmid containing a proximal 5’-upstream
region (-575) of the p27 gene (p27-5’UTR). (b) Moderate increase in the concentration of D-(+)-glucose down-regulated the relative luciferase
activity of p27-5’UTR in MDA-MB-231 cells. This panel also shows that rotenone (inhibitor of NADH dehydrogenase (Complex 1) of the
mitochondrial respiratory oxidation-phosphorylation chain) and AICA riboside (inhibitor of AMPK (5’-AMP-activated protein kinase)) up-regulated
the relative luciferase activity of p27-5’UTR in MDA-MB-231 cells. In contrast, compound C (activator of AMPK) down-regulated the relative
luciferase activity of p27-5’UTR in these cells. Metformin (the most widely prescribed anti-diabetic drug that activates AMPK in the cells by
mechanisms that are dependent on its upstream kinase, the tumor suppressor LKB1) did not either up or down-regulate the relative luciferase
activity of p27-5UTR probably because MDA-MB-231 cells lack LKB1. (c) This panel shows that deficiency of D-(+)-glucose, L-leucine, L-
methionine, L-cysteine, or combination of L-methionine and L-cysteine up-regulated the relative luciferase activity of p27-5’UTR in MDA-MB-231
cells. All assays were performed in triplicates and repeated three times.
Eto Cancer Cell International 2011, 11:31
http://www.cancerci.com/content/11/1/31
Page 5 of 17 
 
Figure 3 Schematic diagram of the four different upstream molecular signaling pathways of p27 expression that could lead to either
increased or decreased expression of p27 in human breast cancer cells in vitro. (a) Previously, we identified and reported four different
upstream molecular signaling pathways of the expression of p27 [1,2]. We also reported previously that 4-hydroxytamoxifen - but not tamoxifen
- up-regulated the expression of p27 by using pathway #1 which consists mainly of receptor tyrosine kinases (RTKs) and mTORC1 [2]. Now, we
hypothesize that (i) moderate increase in the concentration of D-(+)-glucose down-regulates and (ii) deficiency of D-(+)-glucose or certain L-
amino acids up-regulates the expression of p27 using pathway #2 which consists mainly of AMPK and mTORC1. (b) We also identified and
reported previously two additional upstream molecular signaling pathways - namely #3 and #4 - of the expression of p27 [1,2]. (c and e)
Western immunoblot analysis of the effects of D-(+)-glucose deficiency, DMSO, tamoxifen and 4-hydroxytamoxifen on the expression of p27
protein in MDA-MB-231 cells. (d and e) Western immunoblot analysis of the effects of the deficiency of L-leucine, L-methionine or L-cysteine on
the expression of p27 protein in these cells. All assays were performed in triplicates and repeated three times.
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Page 6 of 17Figure 4 Effects of tamoxifen, 4-hydroxytamoxifen, and deficiency of D-(+)-glucose, L-leucine, L-methionine or L-cysteine on the
phosphorylation of 4E-BP1 in MDA-MB-231 cells. (a and e) Western immunoblot analysis of the effects of D-(+)-glucose deficiency, DMSO,
tamoxifen and 4-hydroxytamoxifen on the expression of total 4E-BP1 (eukaryotic translation initiation factor 4E binding protein 1) and (b and e)
phosphorylated 4E-BP1. (c and e) Western immunoblot analysis of the effects of the deficiency of L-leucine, L-methionine, or L-cysteine on the
expression of total 4E-BP1 and (d and e) phosphorylated 4E-BP1. All assays were performed in triplicates and repeated three times. (f) Correlation
between the degree of expression of p27 protein and the degree of down-regulation of the phosphorylated 4E-BP1.
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p27.
(b) Differential effects on the phosphorylation of S6K1
Figure 5a to 5e show that (a) 4-OH-tamoxifen and (b)
deficiency of D-(+)-glucose, L-leucine or L-methionine
did not influence the expression of total S6K1, but they
down-regulated the phosphorylated S6K1. As summar-
ized in the Figure 5f, the degree of down-regulation of
the phosphorylated S6K1 did not appear to be corre-
lated with the degree of expression of p27.
It should be noted that (a) 4-OH-tamoxifen and (b)
deficiency of D-(+)-glucose or certain L-amino acids
exerted differential effects on the degree of down-
regulation of either the phosphorylated 4E-BP1 or
phosphorylated S6K1. For example, (a) 4-OH-tamoxi-
fen preferentially down-regulated the phosphoryla-
tion of 4E-BP1 over S6K1. Conversely, (b) D-
(+)-glucose deficiency preferentially down-regulated
the phosphorylation of S6K1 over 4E-BP1. (c) L-Leu-
cine deficiency significantly down-regulated the
phosphorylation of both 4E-BP1 and S6K1, but to a
much lesser extent. (d) L-Methionine deficiency sig-
nificantly down-regulated the phosphorylation of
only S6K1 and to a much lesser extent; but it did not
significantly down-regulate the phosphorylation of
4E-BP1. Lastly, (e) L-cysteine deficiency did not sig-
nificantly down-regulate the phosphorylation of
either 4E-BP1 or S6K1.
Differential effects of 4-hydroxytamoxifen and deficiency
of D-(+)-glucose on the upstream molecular signaling
pathways of p27 expression: pathways further
downstream of mTORC1
Next, we investigated the effects of tamoxifen, 4-OH-
tamoxifen, and the deficiency of D-(+)-glucose on the
pathways further downstream of mTORC1. They were
(a) hypoxia-inducible factor 1a (HIF-1a), (b) sterol reg-
ulatory element binding protein-1 (SREBP-1) and (c)
phosphorylation of eukaryotic elongation-factor-2 kinase
(eEF2k). The results of the western immunoblot analyses
are presented in Figure 6a to 6e. The effects of L-amino
acid deficiencies were not investigated because they
exerted either only a moderate or no effect on the phos-
phorylation of 4E-BP1 or S6K1.
(a) Differential effects on HIF-1a
HIF-1a has been variably characterized in the literature
as being a protein downstream of 4E-BP1, S6K1 or
both. The results of our western immunoblot analyses
presented in Figure 6a and 6e indicated that D-(+)-glu-
cose deficiency significantly down-regulated the expres-
sion of HIF-1a; but 4-OH-tamoxifen did not. These
results are consistent with the hypothesis that HIF-1a is
a protein primarily downstream of S6K1.
(b) Differential effects on SREBP-1 and phosphorylated
eEF2k
No controversy exists in the literature as to the SREBP1
and eEF2k; the consensus is that they are the proteins
primarily downstream of S6K1. The results of our wes-
tern immunoblot analyses of SREBP1 (Figure 6b and 6e)
and phosphorylated eEF2k at Ser366 (Figure 6c, d and
6e) are consistent with this consensus.
Differential effects of 4-hydroxytamoxifen and deficiency
of D-(+)-glucose or L-leucine on the upstream molecular
signaling pathways of p27 expression: pathways
upstream of mTORC1
The results presented above (Figure 2b) suggested that
NADH dehydrogenase (Complex 1) in the mitochon-
drial respiratory oxidation-phosphorylation chain and 5’-
AMP-activated protein kinase (AMPK) are the two criti-
cal components of the pathway #2 upstream of
mTORC1. In addition to these two proteins, we investi-
gated two other proteins that also appeared to be asso-
ciated with the pathway #2 upstream of mTORC1. They
were mitochondrial ATP Synthase a chain (ATP5A) in
the Complex V of respiratory oxidation-phosphorylation
chain and mitochondrial SIRT3.
(a) Differential effects on the mitochondrial ATP5A
During our preliminary proteomic analysis of the hepa-
tic proteins of genetically obese mice and long-lived
dwarf mice, we observed that mitochondrial ATP5A was
most significantly down-regulated in the liver of leptin-
deficient obese mice relative to the lean control mice.
Conversely, we also observed that mitochondrial ATP5A
was most significantly up-regulated in the liver of long-
lived Ames dwarf mice compared to the normal Ames
mice. Based on these preliminary observations, we
decided to investigate the effects of 4-OH-tamoxifen
and deficiency of D-(+)-glucose or certain L-amino acids
on the expression of mitochondrial ATP5A in the
human MDA-MB-231 breast cancer cells in vitro.
The results of our western immunoblot analyses (Fig-
ure 7a, b and 7e) indicated that 4-OH-tamoxifen did
not influence the expression of mitochondrial ATP5A,
but deficiency of D-(+)-glucose, L-leucine or L-methio-
nine up-regulated it. Deficiency of L-cysteine did not
alter the expression of mitochondrial ATP5A.
(b) Differential effects on the mitochondrial SIRT3
Mitochondrial SIRT3 is one of the seven mammalian
anti-aging and anti-metabolic sirtuins. It was reported
recently that mitochondrial ATP5A forms complex with
and interacts with mitochondrial SIRT3 [24]. Based on
this report, we decided to investigate the effects of 4-OH-
tamoxifen and deficiency of D-(+)-glucose or certain L-
amino acids on the expression of mitochondrial SIRT3 in
the human MDA-MB-231breast cancer cells in vitro.
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Figure 5 Effects of tamoxifen, 4-hydroxytamoxifen, and deficiency of D-(+)-glucose, L-leucine, L-methionine or L-cysteine on the
phosphorylation of S6K1 in MDA-MB-231 cells. (a and e) Western immunoblot analysis of the effects of D-(+)-glucose deficiency, DMSO,
tamoxifen and 4-hydroxytamoxifen on the expression of total S6K1 and (b and e) phosphorylated S6K1. (c and e) Westerm immunoblot analysis
of the effects of the deficiency of L-leucine, L-methionine or L-cysteine on the expression of total S6K1 and (d and e) phosphorylated S6k1. All
assays were performed in triplicates and repeated three times. (f) Correlation between the degree of expression of p27 protein and the degree
of down-regulation of phosphorylated S6k1.
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7c, d and 7e) indicated that deficiency of D-(+)-glucose or
L-leucine - but not 4-OH-tamoxifen - up-regulated the
expression of mitochondrial SIRT3 in these cells. Defi-
ciency of L-methionine or L-cysteine, however, did not
either up or down-regulate the expression of SIRT3.
Finally, 4-OH-tamoxifen and deficiency of D-(+)-glu-
cose or certain L-amino acids did not regulate the
expression of nuclear anti-aging and anti-metabolic pro-
tein SIRT1 in these cells (results not shown).
Discussion
Based on the results presented above, a schematic dia-
gram is presented in Figure 8 that outlines the effects of
4-hydroxitamoxifen, moderate increase in the concentra-
tion of D-(+)-glucose and deficiency of D-(+)-glucose or
 
 
 
Figure 6 Effects of tamoxifen, 4-hydroxytamoxifen and deficiency of D-(+)-glucose on the expression of HIF-1a, SREBP-1 and
phosphorylation of eEF2k in MDA-MB-231 cells. (a and e) Western immunoblot analysis of the effects of D-(+)-glucose deficiency, DMSO,
tamoxifen and 4-hydroxytamoxifen on the expression of HIF1a. (b and e) SREBP-1, (c and e) total eEF2k and (d and e) phosphorylated eEF2k. All
assays were performed in triplicates and repeated three times.
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Figure 7 Effects of tamoxifen, 4-hydroxytamoxifen and deficiency of D-(+)-glucose, L-leucine, L-methionine or L-cysteine on the
expression of mitochondrial ATP5A and SIRT3 in MDA-MB-231 cells. (a and e) Western immunoblot analysis of the effects of D-(+)-glucose
deficiency, DMSO, tamoxifen, 4-hydroxytamoxifen and (b and e) deficiency of L-leucine, L-methionine or L-cysteine on the expression of
mitochondrial ATP5a in the Complex V of respiratory oxidation-phosphorylation system. (c and e) Western immunoblot analysis of the effects of
D-(+)-glucose deficiency, DMSO, tamoxifen, 4-hydroxytamoxifen and (d and e) deficiency of L-leucine, L-methionine or L-cysteine on the
expression of mitochondrial SIRT3. The SIRT3 is one of the seven mammalian anti-aging and anti-metabolic sirtuins. All assays were performed in
triplicates and repeated three times.
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Figure 8 Schematic diagram of the hypothetical molecular signaling pathways of the expression of p27 by which moderate increase
in the concentration of D-(+)-glucose down-regulates and deficiency of D-(+)-glucose or L-leucine up-regulates the expression of p27.
This summary diagram shows the outline of how 4-hydroxytamoxifen uses primarily pathway #1 to up-regulate the expression of p27, arrest the
G1-to-S phase transition of cell cycle, and inhibit DNA replication in human breast cancer cells in vitro. 4-Hydroxytamoxifen preferentially
phosphorylates 4E-BP1 over S6K1. The diagram also shows the outline of how the deficiency of D-(+)-glucose uses primarily pathway #2 to up-
regulate the expression of p27, arrest the G1-to-S phase transition of cell cycle, and inhibit DNA replication in human breast cancer cells in vitro.
D-(+)-Glucose deficiency preferentially phosphorylates S6K1 over 4E-BP1. The diagram also shows that the deficiency of L-leucine enters the
pathway #2 at points different from the deficiency of D-(+)-glucose. Finally, the diagram shows that deficiency of D-(+)-glucose or L-leucine uses
L-upstream molecular signaling pathway #2 of the expression of p27 to up-regulate the phosphorylation of AMPK and the expression of
mitochondrial ATP5A and SIRT3. The mitochondrial SIRT3 exerts anti-aging and other metabolic effects on the cells.
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molecular signaling pathways of the expression of p27
in human breast cancer cells in vitro. The results pre-
sented are consistent with the following hypotheses,
namely:
(a) 4-Hydroxitamoxifen up-regulates the expression
p27 in human breast cancer cells in vitro primarily by
using pathway #1. The pathway #1 consists mainly of
receptor tyrosine kinases/phosphoinositide-3-kinase/
Akt/tuberous sclerosis complex/mammalian target of
rapamycin complex 1/eukaryotic translation initiation
factor 4E-binding protein 1 (RTKs/PI3K/Akt/TSC/
mTORC1/4E-BP1).
(b) Moderate increase in the concentration of D-
(+)-glucose or certain amino acids down-regulates and
deficiency of D-(+)-glucose or L-leucine up-regulates
the expression of p27 in human breast cancer cells in
vitro primarily by using pathway #2. The pathway #2
consists mainly of 5’-AMP-activated protein kinase/
tuberous sclerosis complex/mammalian target of rapa-
mycin complex 1/p70 S6 kinase I (AMPK/TSC/
mTORC1/S6K1). The pathway #2 also modulates the
phosphorylation of 4E-BP1 thereby regulating the
expression of p27, but this effect is secondary to its
effect on the phosphorylation of S6K1.
Down-regulation of the phosphorylation of S6K1 in
the pathway #2 by the deficiency of D-(+)-glucose
resulted in the (i) down-regulation (de-stabilization) of
HIF-1a, (ii) up-regulation (stabilization) of SREBP1
and (iii) down-regulation of the phosphorylation of
eEF2k.
The SREBP1 is of particular interest here because
SREBP1 has recently been implicated in the insulin
resistance of type 2 diabetes. It is well known that, in
the liver of many insulin-resistant mouse models, insulin
fails to suppress D-(+)-glucose production (gluconeo-
genesis) but continue to promote lipid synthesis. It is
also known that mTORC1 down-regulates (activates or
de-stabilizes) SREBP-1 and thereby uncouples lipogen-
esis from gluconeogenesis [25]. This down-regulation of
t h ee x p r e s s i o no fS R E B P 1b ym T O R C 1a p p e a r st ob e
achieved at least in part by promoting its posttransla-
tional processing via S6K1, which in turn leads to the
increased transcription of genes involved in sterol and
lipid biosynthesis and the oxidative arm of the pentose-
phosphate pathway [26,27]. mTORC1-mediated decrease
in (or activation or de-stabilization of) the expression of
SREBP-1 also appears to be necessary for lipogenesis
induced by Akt [28]. In summary, our results suggested
that the deficiency of D-(+)-glucose could suppress insu-
lin resistance and restore insulin sensitivity by down-
regulating the phosphorylation of S6K1 and up-regulat-
ing (de-activating or stabilizing) the expression of
SREBP1,
Deficiency of D-(+)-glucose or L-leucine - but not 4-
hydroxitamoxifen - up-regulates the expression of
mitochondrial ATP Synthase a chain (ATP5A) in the
Complex V of respiratory oxidation-phosphorylation chain
During our preliminary proteomic analysis of the hepa-
tic proteins of leptin-deficient obese mice and long-lived
dwarf mice, we observed that the expression of mito-
chondrial ATP5A protein was most significantly down-
regulated in the liver of leptin-deficient obese mice rela-
tive to the lean control mice. We also observed that
ATP5A protein was most significantly up-regulated in
the liver of long-lived Ames dwarf mice relative to the
normal Ames mice.
Based on these findings, we decided to investigate and,
in fact, reported, as described above in the results sec-
tion, that the deficiency of D-(+)-glucose, L-leucine or
L-methionine up-regulated the expression of mitochon-
drial ATP5A in the human MDA-MB-231 breast cancer
cells in vitro as well.
As to the possible molecular mechanisms of the up-
regulation of ATP5A, we realized that almost no study
was published in the literature. One exception was the
study published in 2010, where authors speculated that,
as wakefulness continues in mice, the maintenance of
ATP becomes more challenging and likely to involve
additional nuclear transcriptional mechanisms [29]. The
authors further stated that, initially, the demand for
increased ATP during wakefulness is met by increased
activity of the mitochondrial respiratory oxidation-phos-
phorylation (OxPhos) system (including ATP5B and
probably ATP5A as well). This would eventually lead to
an increase in the production of reactive oxygen species
(ROS) during extended wakefulness that would then
lead to uncoupling with at least temporary decline in
ATP and increase in AMP resulting in the activation
(increased phosphorylation) of 5’-AMP-dependent pro-
tein kinase (AMPK).
This study [29] places the molecular basis of the
metabolic up-regulation of the expression of ATP5A by
the deficiency of D-(+)-glucose or L-leucine at the
AMPK, which is one of the essential components of the
pathway #2 in the upstream molecular signaling path-
ways of p27 expression.
Deficiency of D-(+)-glucose or L-leucine - but not 4-
hydroxitamoxifen - up-regulates the expression of
mitochondrial SIRT3, one of the seven mammalian anti-
aging and anti-metabolic sirtuins
Mitochondrial SIRT3 is one of the seven mammalian
sirtuins that are involved in anti-aging and other meta-
bolic processes. Recently, it was reported that mitochon-
drial SIRT3 forms complex with and interacts with
mitochondrial ATP5A [24]. Since SIRT3 is known to be
present ubiquitously in the body, we speculated that
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231 breast cancer cells in vitro and, in fact, as described
in the results section above, we found that deficiency of
D-(+)-glucose or L-leucine - but not 4-hydroxytamoxi-
fen - up-regulated the expression of SIRT3 in these
cells.
Sirtuins are a family of NAD
+-dependent protein dea-
cetylases that regulate cellular functions through deace-
tylation of a wide range of protein targets [24,30-34].
Overexpression of Sir2, the first gene discovered in this
family, is able to extend the life span in various organ-
isms. The anti-aging effects of human homologues of
s i r t u i n s ,S I R T 1 - 7 ,h a v ea l s ob e e ns u g g e s t e db ya n i m a l
and human studies.
The results of our study are consistent with the notion
that deficiency of D-(+)-glucose or L-leucine - but not
4-hydroxytamoxifen - could exert anti-aging and other
metabolic effects through the pathway that involves
AMPK, ATP5A and SIRT3. It has been reported, in fact,
that the expression of mitochondrial SIRT3 may be up-
regulated in caloric restriction and down-regulated in
obesity and diabetes [35,36]. It has also been reported
that the activation (increased phosphorylation) of
AMPK may lead to up-regulation of the expression of
mitochondrial SIRT3 [37].
Thus, the origin of the metabolic up-regulation of the
expression of mitochondrial SIRT3 by the deficiency of
D-(+)-glucose or L-leucine could be traced to AMPK,
which is again one of the essential components of the
pathway #2 in the upstream molecular signaling path-
ways of p27. expression.
Conclusions
Previously, we identified and reported four different
upstream molecular signaling pathways - we called them
pathway #1, #2, #3 and #4 - of the expression of p27 in
human breast cancer cells in vitro. Based on the results
presented above, we conclude that:
(a) 4-Hydroxitamoxifen uses primarily pathway #1 to
up-regulate the expression of p27. The pathway #1 con-
sists mainly of receptor tyrosine kinases (RTKs) and
mammalian target of rapamycin complex 1 (mTORC1).
(b) Moderate increase in the concentration of D-
(+)-glucose is likely to use primarily pathway #2 to
down-regulate the expression of p27. The pathway #2
consists mainly of 5’-AMP-activated protein kinase
(AMPK) and mTORC1 protein kinase.
(c) Deficiency of D-(+)-glucose or L-leucine uses pri-
marily pathway #2 to up-regulate the expression of p27.
(d) Additionally, deficiency of D-(+)-glucose or L-leu-
cine - but not 4-hydroxytamoxifen - also up-regulates the
expression of mitochondrial ATP5A in the Complex V of
respiratory oxidation-phosphorylation chain and mito-
chondrial anti-aging as well as anti-metabolic SIRT3.
Methods
Reagents
4-Hydroxytamoxifen, tamoxifen, D-(+)-glucose, and
rotenone were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Compound C and metformin were obtained
from Calbiochem/EMD (San Diego, CA, USA). AICA
riboside was purchased from Phoenix Pharmaceuticals,
Inc. (Belmont, CA, USA). Dulbecco’s Modified Eagle’s
Medium (DMEM) Labeling Kit was purchased initially
from Chemicon International (Temecula, CA, USA) and
later from EMD Millipore (Billerica, MA, USA).
The following antibodies were purchased from Cell
Signaling Technology, Inc. (Danvers, MA, USA): namely
(a) total 4E-BP1 and phospho-4E-BP1 (Thr37/46); (b)
total S6K1 and phospho-S6K1 (Thr389); and (c) total
eEF2k and phospho-eEF2k (Ser366). Additionally, the
following antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA): namely (a)
p27, (b) GAPDH, (c) ATP5A, (d) SIRT3, (e) SIRT1, (f)
SREBP-1, and (g) HIF-1a.
Cell Cultures
Human MDA-MB-231 breast cancer cells (estrogen
receptor (ER) and LKB1-double negative) were pur-
chased from the American Type Culture Collection
(Rockville, MD, USA). The cells were grown in Dul-
becco’s Modified Eagle’s Medium (DMEM) containing
4.5 g/L of D-(+)-glucose, supplemented with 10%
heat-inactivated FBS, 2% L-glutamine, and antibiotics/
antimycotics. Incubation of the cells was carried out
at 37°C in a 5% CO2 humidified chamber. The cells
were subcultured after trypsinization with 0.05% tryp-
sin-0.02% EDTA solution. The cells were always
maintained below confluency and checked periodically
for mycoplasmal infection by DNA fluorochrome
staining.
Plasmids
Luciferase reporter plasmids containing one of the fol-
lowing proximal 5’-upstream regions of the p27 gene
were used to transfect the human MDA-MB-231 breast
cancer cells: -1797 p27 (p27-Kpn I) [38], -774 p27 (p27-
Apa I) [38], and -575 p27 (p27-5’UTR) [4,8]. The con-
trol luciferase reporter plasmids not containing these
inserts were also prepared and used to test if 24-hour
treatment of the cells with DMSO, 4-hydroxytamoxifen,
tamoxifen, excess D-(+)-glucose, or the deficiency of D-
(+)-glucose, L-leucine, L-methionine, L-cysteine, or
combination of L-methionine and L-cysteine was exert-
ing any spurious effects on the backbone, rather than
the insert, of the luciferase reporter plasmids. None of
these treatments were found to exert any spurious
effects on the backbone of the plasmids in the human
MDA-MB-231 breast cancer cells.
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Transfections were performed according to the pub-
lished protocol [39] using FuGENE 6 obtained from
Roche Applied Science (Indianapolis, IN, USA). In brief,
24 hours before reporter transfection, the cells were
seeded into a 60-mm tissue culture dish at a density of
1.5 × 10
5 cells/dish and incubated at 37°C in a 5% CO2
humidified chamber. Transfection of the luciferase
reporter plasmid was then carried out with 1 μg of luci-
ferase reporter plasmid and 0.2 μgo fp S V - b-galactosi-
dase internal control plasmid (Promega, Madison, WI,
USA) mixed with 3 μLo fF u G E N E6s o l u t i o ni n3m L
of FBS-free DMEM supplemented with only 2% L-gluta-
mine. A minimum of 5-hour incubation at 37°C was
needed for transient transfection, followed by 18-hour
incubation in DMEM with 10% FBS for recovery. The
transfected cells were then starved in DMEM with 0.2%
FBS for 24 hours. Subsequently, the resulting cells were
cultured either (a) in the presence of DMSO, tamoxifen,
or 4-hydroxytamoxifen in the regular DMEM with 0.2%
FBS, (b) in the presence of a moderate increase in the
concentration of D-(+)-glucose or (c) deficiency of D-
(+)-glucose, L-leucine, L-methionine, L-cysteine or com-
bination of L-methionine and L-cysteine in the appro-
priately supplemented basal DMEM Labeling Kit as
described in the figure legends. After 24 hours, the trea-
ted cells were collected and lysed using Reporter Lysis
B u f f e r( P r o m e g a ,M a d i s o n ,W I )a n dt h er e s u l t i n gc e l l
lysates were assayed for luciferase activity using Lucifer-
ase Assay Kit (Promega, Madison, WI, USA) and TD-
20/20 Luminometer (Turner Designs, Sunnyvale, CA,
USA). b-Galactosidase activity was measured using
chlorophenol red-b-D-galactopyranoside (CPRG)
(Sigma-Aldrich, St. Louis, MO, USA) as a substrate.
Each luciferase activity driven by a specific proximal
5’-upstream region of the p27 gene was normalized to
b-galactosidase activity in order to control for variations
in transfection efficiency.
As for the issue of whether the expression of p27 was
regulated primarily at the level of translation, we per-
formed the following three different studies:
(a) The various deletion constructs of -1797 p27-Kpn1
luciferase reporter plasmids were used to determine the
core element of the activation of the proximal 5’-
upstream region (-1797) of p27 gene [1,2]. The results
indicated that various nutritional and chemopreventive
anti-cancer agents, including tamoxifen and 4-hydroxy-
tamoxifen, activated the proximal 5’-upstream region
(-1797) of p27 gene through its 5’-untranslated region
(5’UTR) (-575). It is well established that this region
mediates the cap-independent translation initiation of
p27 mRNA [4-10].
(b) To investigate if -575 p27 (p27-5’UTR) contains
any cryptic transcription factor binding sites - in other
words, if the expression of p27 is regulated primarily at
the level of transcription - the luciferase activity of the
region was stimulated with 4-hydroxytamoxifen in the
presence of an adequate dose of antibiotic actinomycin
D [1,2]. Actinomycin D is a well-known inhibitor of
transcription. The results indicated that the -575 p27
(5’-untranslated region (5’UTR)) is unlikely to contain
any cryptic transcription factor binding sites. This assay
was performed not only with tamoxifen and 4-hydroxy-
tamoxifen, but also with many other anti-cancer agents.
(c) Depending on the cell types, it was observed from
time to time that control vector expression was affected
by each treatment and also there could be cell cycle
effects probably changing with treatment. To exclude
these possibilities, the p27 luciferase reporter vector that
does not contain and insert of the specific proximal 5’-
upstream region of the p27 gene was prepared and
tested using the same anti-cancer agents and cell types
[1,2]. In these exceptional cases, the following formula
was used to correct this false increase in the relative
luciferase activity:
Relative luciferase activity (% ) = (Experimental luciferase activity/Control luciferase activity)×100,
where,
(1) Experimental luciferase activity = {Test com-
pound/None}{Luciferase reporter vector containing a
specific insert},
(2) Control luciferase activity = {Test compound/
None}{Luciferase reporter vector NOT containing a
specific promoter insert}, and
( 3 )T e s tc o m p o u n d / N o n e=[ L u c ( T e s t ) / bGal(Test)]/
[Luc(None)/bGal(None)].
The human MDA-MB-231breast cancer cells that
were used in this study did not present any of these
exceptional problems. For additional information on this
and related issues, please refer to the reference #40 [40].
Western Immunoblot Analysis
Western immunoblot analysis of the upstream molecu-
lar signaling pathways of the expression of p27 was per-
formed using estrogen receptor (ER) and LKB1-double
negative human MDA-MB-231 breast cancer cells in
vitro. This analysis was performed without either trans-
fecting the cells with various proximal 5’-upstream
region of p27 gene-luciferase reporter plasmids or add-
ing any growth factors to avoid the artificial stimulation
of the cell proliferation.
In brief, the cells were seeded at a density of 5.5 × 10
6
cells/dish into a 100-mm tissue culture dish containing
10 mL of DMEM supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS), 2% L-glutamine, and
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a5 %C O 2 humidified chamber for 24 hours. After 24
hours, the cells were partially synchronized for another
24 hours in DMEM containing only 0.2% (v/v) of FBS.
Subsequently, the resulting cells were cultured either (a)
in the presence of DMSO, tamoxifen, or 4-hydroxyta-
moxifen in the regular DMEM with 0.2% FBS or (b) in
the presence or absence of D-(+)-glucose, L-leucine, L-
methionine, or L-cysteine in the appropriately supple-
mented basal DMEM Labeling Kit as described in the
figure legends. After 24 hours, the cells were washed
twice with cold 1× PBS and scraped in 1× RIPA Lysis
Buffer (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) containing phenylmethylsulphonyl fluoride
(PMSF), protease inhibitor cocktail, sodium orthovana-
date and 50 mM NaF. The cells were then sonicated
and the supernatant was collected by centrifugation and
stored at -80°C.
The supernatants (60 μg protein/lane) were applied to
the SDS-PAGE and, after fractionation, proteins were
transferred to nitrocellulose membrane, which was then
blocked and incubated in a solution containing first pri-
mary antibody. After shaking overnight at 4°C, the target
proteins bound to the first primary antibody were
further incubated in a solution containing alkaline phos-
phatase (AP)-conjugated secondary anti-immunoglobu-
lin antibody and detected by chemiluminescence using
TROPIX Western-Star Kit (Applied Biosystems, Foster
City, CA, U.S.A.). After exposure to X-ray film, the blots
were stripped using Western Re-Probe Solution (G-Bios-
ciences, St. Louis, MO, U.S.A.), checked for removal of
the chemiluminescence and then re-probed with second
primary antibody.
Densitometric measurement of the intensity of the
bands on the X-ray film was performed using UN-
SCAN-IT Gel & Graph Digitizing Software Version 6.1
(Silk Scientific Corporation, Orem, UT, U.S.A.). Back-
ground corrections were done by four corner interpola-
tion and optical density calculations were performed
Statistical Analysis
An experimental value with statistical significance of P ≤
0.05 compared to the control by t test is indicated as a
single asterisk on top of the vertical bar.
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